<DOC>
	<DOCNO>NCT01739517</DOCNO>
	<brief_summary>This pilot study seek demonstrate efficacy intravenous lipid preparation high omega-3 fatty acid ( Omegaven ) treatment cholestasis parenteral nutrition dependent patient short gut syndrome .</brief_summary>
	<brief_title>Efficacy Safety Omega-3 Lipid Therapy Pediatric Patients With Parenteral Nutrition-Associated Liver Disease</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Cholestasis</mesh_term>
	<mesh_term>Short Bowel Syndrome</mesh_term>
	<criteria>Patient dependent upon parenteral nutrition ( PN ) Patient short gut syndrome ( loss &gt; 50 % small bowel ) Patient 's guardian/caregiver provide informed consent patient receive therapy Pediatric patient â‰¤ 1 year age Expected PN duration great 30 day Direct bilirubin &gt; 2.0 mg/dL measure two occasion one week apart Liver dysfunction secondary cause PN verify standard care diagnostic procedure lab work rule alternative cause neonatal cholestasis . Any patient Omegaven therapy would contraindicate , allergy seafood product , egg protein , and/or previously establish allergy Omegaven impair lipid metabolism severe hemorrhagic disorder unstable diabetes mellitus collapse shock , stroke/embolism , recent cardiac infarction , undefined coma status</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>1 Year</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Short bowel syndrome</keyword>
	<keyword>Cholestasis</keyword>
	<keyword>Omegaven</keyword>
	<keyword>Parenteral nutrition-associated Liver Disease</keyword>
</DOC>